1Bureh D, Bieshuevel E, Smith S, et al. Can endometrial protection be inferred from the bleeding pattern on combined cyclical hormone replacement therapy [ J ]. Maturitas, 2000, 34 (2) : 155 - 160.
2Sator MO, Nagele F, Sator P, et al. Clinical profile of a new hormone replacement therapy containing 2 mg 17 beta - estradiol and 10 mg dydrogesterone [J]. Maturitas, 2000, 34(3) :267 - 273.
3Bergeron C, Ferenczy A. Endometrial safety of continuous combined hormone replacement therapy with 17 beta - oestradiol (1 or 2 nag) dydrogesterone [ J ]. Maturitas, 2001, 37 (3) : 191 - 199.
5De Franciscis P, Cobellis L, Fomaro F, et al. Low-dose hormone therapy in the perimenopause [J]. International Journal of Gynecology & Obstetrics, 2007, 98 (2) : 138 - 142.
6Di Carlo C, Sammartino A, Sardo AD, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy [ J ]. Menopause -the Journal of the North American Menopause Society, 2005, 12(5) :520 -525.
7Adiyono W, Hardian. TNF -alpha and IL- 8 profile after dydrogesterone therapy on dysfunctional uterine bleeding patients. Third World Congress on Controversies in Obstetrics Gynecology & Infertility [ C ]. 2002 : 11 - 4
8Foumier A, Berrino F, Clavel- Chapelon F, Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3 N cohort study [ J ]. Breast Cancer Research and Treatment, 2008, 107( 1 ) :103 - 11.
9Campagnoli C, Abba C, Ambroggio S, et al. Differential effects of various progestogens on metabolic risk factors for breast cancer [J]. Gynecological Endocrinology, 2007, 23 ( S1 ) :22 - 31.
10Chetrite GS, Thole HH, Philippe JC, et al. Dydrogesterone ( Duphastan (R) ) and its 20 - dihydro - derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17 beta - hydroxysteroid dehydrogenase (17 beta - HSD) activity [J]. Antieancer Research, 2004, 24 (3A) :1433 - 1438.
